Table 5. Association between rs2296651 and LC, HCC in present study.
RS ID | Model | Genotype | HC | CHB | LC | HCC | AOR1 | P1 | AOR2 | P2 | AOR3 | P3 | AOR4 | P4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rs2296651 | Alleles | G | 2172(89.3) | 1682(98.5) | 452(95.4) | 229(97.9) | 1 | 1 | 1 | 1 | ||||
A | 260(10.7) | 26(1.5) | 22(4.6) | 5(2.1) | 0.532 (0.328-0.861) | 0.01 | 1.95 (1.08-3.521) | 0.026 | 0.519 (0.273-0.99) | 0.046 | 0.866 (0.292-2.575) | 0.796 | ||
Codominant | GG | 956(78.6) | 828(96.8) | 216(90.8) | 112(95.7) | 1 | 1 | 1 | 1 | |||||
GA | 260(21.4) | 26(3.0) | 20(8.4) | 5(4.3) | 0.341 (0.211-0.549) | 0.001 | 2.934 (1.607-5.358) | 0.003 | 0.46 (0.254-0.832) | 0.008 | 1.422 (0.535-3.778) | 0.484 | ||
AA | 0(0) | 1(0.1) | 1(0.8) | 0(0) | NA | NA | NA | NA | NA | NA | ||||
Dominant | GG+GA | 1216(100) | 854(99.9) | 236(99.2) | 117(100) | 1 | 1 | 1 | 1 | |||||
AA | 0(0) | 1(0.1) | 1(0.8) | 0(0) | NA | NA | 2.033 (1.083-3.818) | 0.027 | NA | NA | 0.889 (0.290-2.731) | 0.837 | ||
Recessive | AA+GA | 260(21.4) | 27(3.1) | 21(8.8) | 5(4.3) | 1 | 1 | 1 | 1 | |||||
GG | 956(78.6) | 828(96.9) | 216(91.2) | 112(95.7) | 0.499 (0.306-0.818) | 0.001 | 2.994 (0.186-48.26) | 0.44 | 0.52 (0.273-0.99) | 0.041 | NA | NA | ||
Additive | 0.532 (0.328-0.861) | 0.01 | 1.95 (1.08-3.521) | 0.026 | 0.519 (0.273-0.99) | 0.046 | 0.866 (0.292-2.575) | 0.796 |
LC, liver cirrhosis. HCC, hepatocellular carcinoma. Data were presented as number (percentage) for every group. The differences in genotype frequencies between any two groups were analyzed using logistic regression models (Codominant, Recessive, Dominant, additive). Age and sex were included as covariates. AOR1 and P1, Comparison of patients with LC to HC. AOR2 and P2, Comparison of patients with LC to CHB. AOR3 and P3, Comparison of patients with HCC to HC. AOR4 and P4, Comparison of patients with HCC to CHB. AOR(95% CI), adjusted odds ratio was calculated and reported within the 95% confidence interval. Significant p-values (p < 0.05) were highlighted in bold.